Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimonabant in Non-diabetic NASH
NCT00576667Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Jan 2008
- Primary completion
- Feb 2009
- Modality
- Small Molecules
- Countries
- 24
01
Overview
Phase 3, randomised, double-blind trial in Nonalcoholic steatohepatitis (NASH) comparing Rimonabant with Placebo (2 arms). Primary endpoint: NAFLD Activity Score at 24 months. Started Jan 2008; status: terminated.
02
Drugs
rimonabant
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT00576667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00576667.